Abstract

Background: Pseudomonas aeruginosa (P. aeruginosa) is a ubiquitous gram-negative rod shaped bacteria and a significant nosocomial opportunistic pathogen. Current study aimed at the investigation and determination of extended-spectrum beta-lactamase (ESBL) positive P. aeruginosa from clinical samples.
 Materials and methods: A total of 150 catheter tubes, pus, blood, and sputum samples were collected from three different hospitals in the twin cities of Rawalpindi and Islamabad. The isolates were identified by using standard microbiology procedures. Antibiotic susceptibility of the isolates was done through the disc diffusion method as per the protocol given by CLSI guidelines. Phenotypic characterization of ESBL producers was performed by combination disc test (CDT), double disc synergy test (DDST) and through PCR.
 Results: A total of 77/218 isolates were identified as P. aeruginosa. Among them 47 were resistant to different drugs, while 28 were identified as multidrug resistant. They were resistant to 9 different drugs including Cefotaxime (49%), Cefipime (41%), Cephradine (32%), Cefotetan (62%), Azetronam (50%), Cofaclor (42%), Ticarcillin (57%), Ciproflaxacin (45%), and Imipenem (36%). CDT and DDST showed that 7/29 isolates produce ESBL. One isolate was positive for VEB and 3 were positive for SHV ESBL genotype.
 Conclusion: The phenomenon of ESBL production does not only remain in Klebsiella pneumonia and Escherichia coli but could also be found in P. aeruginosa. Moreover, SHV genotype is prevalent in local isolates of P. aeruginosa.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.